Your browser doesn't support javascript.
loading
Correlation of Morphological Appearance of Peritoneal Lesions at Laparotomy and Disease at Pathological Assessment in Patients Undergoing Cytoreductive Surgery for Peritoneal Malignancy: Results of Phase I of the PRECINCT Study in 707 Patients.
Bhatt, Aditi; Villeneuve, Laurent; Sardi, Armando; Souadka, Amine; Buseck, Alison; Moran, Brendan J; Khannousi, Basma El; de Pedro, Carlos Gonzalez; Baratti, Dario; Biacchi, Danielle; Morris, David; Labow, Daniel; Levine, Edward A; Mohamed, Faheez; Adeleke, Gbadebo; Goswami, Gaurav; Bonnefoy, Isabelle; Perry, Katherine Cummins; Votanopoulos, Konstantinos I; Parikh, Loma; Deraco, Marcello; Alyami, Mohammad; Cohen, Noah; Benzerdjeb, Nazim; Shah, Nehal; Bahaoui, Nezha El; Khajoueinejad, Nazanin; Rousset, Pascal; Shen, Perry; Barat, Shoma; Stanford, Sophia; Khouchoua, Selma; Troob, Samantha; Shaikh, Sakina; Sarpel, Umut; Gushchin, Vadim; Samuel, Vasanth Mark; Kepenekian, Vahan; Sammartino, Paolo; Glehen, Olivier.
Afiliação
  • Bhatt A; Department of Surgical Oncology, Zydus Hospital, Ahmedabad, India.
  • Villeneuve L; Department of Clinical Research, Centre-Hospitalier Lyon-sud, Lyon, France.
  • Sardi A; Department of Surgical Oncology, Mercy Medical Centre, Baltimore, MD, USA.
  • Souadka A; Department of Surgical Oncology, National Cancer Institute, Rabat, Morocco.
  • Buseck A; Department of Surgical Oncology, Mercy Medical Centre, Baltimore, MD, USA.
  • Moran BJ; Department of Surgical Oncology, Peritoneal Malignancy Institute, Basingstoke, UK.
  • Khannousi BE; Department of Pathology, National Cancer Institute, Rabat, Morocco.
  • de Pedro CG; Department of Surgical Oncology, Hospital Universitario Virgen del Rocio, Sevilla, Spain.
  • Baratti D; Department of Surgical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Biacchi D; Department of Surgical Oncology, Sapienza University of Rome, Rome, Italy.
  • Morris D; Department of Surgical Oncology, St. George Hospital, Sydney, NSW, Australia.
  • Labow D; Department of Surgical Oncology, Mount Sinai Hospital, New York, NY, USA.
  • Levine EA; Section of Surgical Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
  • Mohamed F; Department of Surgical Oncology, Peritoneal Malignancy Institute, Basingstoke, UK.
  • Adeleke G; Department of Pathology, Peritoneal Malignancy Institute, Basingstoke, UK.
  • Goswami G; Department of Radiology, Zydus Hospital, Ahmedabad, India.
  • Bonnefoy I; Department of Clinical Research, Centre-Hospitalier Lyon-sud, Lyon, France.
  • Perry KC; Section of Surgical Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
  • Votanopoulos KI; Section of Surgical Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
  • Parikh L; Department of Pathology, Zydus Hospital, Ahmedabad, India.
  • Deraco M; Department of Surgical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Alyami M; Department of Surgical Oncology, King Khaled Hospital, Najran, Saudi Arabia.
  • Cohen N; Department of Surgical Oncology, Mount Sinai Hospital, New York, NY, USA.
  • Benzerdjeb N; Department of Pathology, Centre Hospitalier Lyon-sud, Lyon, France.
  • Shah N; Department of Pathology, National Cancer Institute, Rabat, Morocco.
  • Bahaoui NE; Department of Surgical Oncology, National Cancer Institute, Rabat, Morocco.
  • Khajoueinejad N; Department of Surgical Oncology, Mount Sinai Hospital, New York, NY, USA.
  • Rousset P; Department of Radiology, Centre Hospitalier Lyon-sud, Lyon, France.
  • Shen P; Section of Surgical Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
  • Barat S; Department of Surgical Oncology, St. George Hospital, Sydney, NSW, Australia.
  • Stanford S; Department of Clinical Research, Peritoneal Malignancy Institute, Basingstoke, UK.
  • Khouchoua S; Department of Radiology, National Cancer Institute, Rabat, Morocco.
  • Troob S; Department of Surgical Oncology, Mount Sinai Hospital, New York, NY, USA.
  • Shaikh S; Department of Surgical Oncology, Zydus Hospital, Ahmedabad, India.
  • Sarpel U; Department of Surgical Oncology, Mount Sinai Hospital, New York, NY, USA.
  • Gushchin V; Department of Surgical Oncology, Mercy Medical Centre, Baltimore, MD, USA.
  • Samuel VM; Department of Surgical Oncology, Peritoneal Malignancy Institute, Basingstoke, UK.
  • Kepenekian V; Department of Surgical Oncology, Centre Hospitalier Lyon-sud, Lyon, Pierre Bénite, France.
  • Sammartino P; Department of Surgical Oncology, Sapienza University of Rome, Rome, Italy.
  • Glehen O; Department of Surgical Oncology, Centre Hospitalier Lyon-sud, Lyon, Pierre Bénite, France. olivier.glehen@chu-lyon.fr.
Ann Surg Oncol ; 2024 Aug 26.
Article em En | MEDLINE | ID: mdl-39187665
ABSTRACT

BACKGROUND:

The PRECINCT (Pattern of peritoneal dissemination and REsponse to systemic Chemotherapy IN Common and uncommon peritoneal Tumors) is a prospective, multicenter, observational study. This report from phase I of PRECINCT outlines variations in recording the surgical peritoneal cancer index (sPCI) at experienced peritoneal malignancy centers and the incidence of pathologically confirmed disease in morphologically different peritoneal lesions (PL).

METHODS:

The sPCI was recorded in a prespecified format that included the morphological appearance of PL. Six prespecified morphological terms were provided. The surgical and pathological findings were compared.

RESULTS:

From September 2020 to December 2021, 707 patients were enrolled at 10 centers. The morphological details are routinely recorded at two centers, structure bearing the largest nodule, and exact size of the largest tumor deposit in each region at four centers each. The most common morphological terms used were normal peritoneum in 3091 (45.3%), tumor nodules in 2607 (38.2%) and confluent disease in 786 (11.5%) regions. The incidence of pathologically confirmed disease was significantly higher in 'tumor nodules' with a lesion score of 2/3 compared with a lesion score of 1 (63.1% vs. 31.5%; p < 0.001). In patients receiving neoadjuvant chemotherapy, the incidence of pathologically confirmed disease did not differ significantly from those undergoing upfront surgery [751 (47.7%) and 532 (51.4%) respectively; p = 0.069].

CONCLUSIONS:

The sPCI was recorded with heterogeneity at different centers. The incidence of pathologically confirmed disease was 49.2% in 'tumor nodules'. Frozen section could be used more liberally for these lesions to aid clinical decisions. A large-scale study involving pictorial depiction of different morphological appearances and correlation with pathological findings is indicated.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article